Cornea/External Disease News

Stuart Therapeutics has announced the first patient first visit for its phase 3 clinical trial of ST-100 ophthalmic solution for patients with dry eye disease.

Keratoconus may be associated with ADHD in male patients, according to a study recently published in JAMA Ophthalmology.

The top Healio cornea-related articles in 2023 included the FDA approval of Vevye for dry eye disease and the efficacy of azithromycin in the treatment of meibomian gland dysfunction.

The FDA granted orphan drug designation for Cellusion’s CLS001, a corneal endothelial cell substitute for bullous keratopathy, according to a press release.

The office-based thermal eyelid treatment TearCare significantly improved tear breakup time and measures of meibomian gland secretion compared with Restasis in patients with dry eye disease, according to 6-month trial data.

Throughout the year, Healio publishes a host of blogs on topics ranging from common conditions like keratoconus and glaucoma to crossover care that includes concussion management and diseases of the brain.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Ashvin Agarwal, MD, overviews his video on traumatic iridodialysis repair.

Nordic Pharma has acquired Visant Medical through its subsidiary Amring Pharmaceuticals.

Azura Ophthalmics announced positive topline results from its phase 2 study of AZR-MD-001 in patients with contact lens discomfort and signs of meibomian gland dysfunction.

Oculis has announced the first patient first visit in its phase 2b RELIEF trial evaluating licaminlimab, the company’s novel anti-tumor necrosis factor-alpha biologic eye drop, for treatment of moderate to severe dry eye disease.